ACR Convergence 2025| Video: Rheum for Everyone, Episode 26—Ableism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Differentiating POTS from Other Conditions

Mary Beth Nierengarten  |  November 6, 2025

Picking up on the symptom of small-fiber neuropathy, one audience member asked about the use of intravenous immunoglobulin in patients with POTS. Dr. Adler said that the question reflected a broader curiosity among rheumatologists about the role of immune dysregulation in POTS and postinfectious chronic illness and what that may mean for treatment. “The possibility that a subset of patients may have an autoimmune etiology raises important questions about when immunotherapy might be appropriate,” she said.

Dr. Adler urged rheumatologists to consider dysautonomia when making a differential diagnosis of a patient, saying that not doing so risks misinterpreting symptoms and managing patients in ways that don’t address their underlying physiology. “By recognizing POTS, we can provide more accurate diagnoses, guide appropriate referrals and improve quality of life for patients who feel misunderstood,” she said.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Management of POTS

Mr. Albert Mears

Mr. Albert Mears

As a physical therapist, Mr. Mears has been treating POTS for about a decade, and he reinforced the need for an interdisciplinary approach to treatment that includes physical therapy, occupational therapy and speech language pathology therapy. All of these treatment approaches, he said, overlap but each provides specific rehabilitation needs that drives the main goal of management: improving functional capacity.

As a physical therapist, Mr. Mear’s first aim is to narrow the scope of the myriad symptoms with which patients with POTS present, such as whether the patient has heart palpitations, dizziness, fatigue, brain fog or unrestful sleep. Any or all of these symptoms can decrease functional capacity due to poor activity tolerance, emphasizing that poor activity tolerance is the real issue underlying patients with POTS.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

He said that therapy starts with understanding the limits of what a patient can do: how much stress can they tolerate while still allowing a timely recovery. To assess this, he uses both subjective and objective measures.

Subjective measures include assessing what a patient’s daily demands are and how well they are tolerated, such as sleep hygiene and how long it takes for them to get up and get going. Mr. Mears uses two subjective scales, the Brief Questionnaire of Exertional Malaise and the Malmo POTS score. He said he gets a pretty good idea of how a patient’s daily living functioning is once he gets the scores from these tests.

He then makes an objective assessment that includes a Static Standing Tolerance Test at every visit. In the test, patients stand for 10 minutes and are asked how they feel while their vital signs are also measured. Other measures include gait speed, a six-minute walk test and an exercise tolerance test. For higher functioning patients, he uses the Functional Index Tool, which is good for measuring endurance.

Page: 1 2 3 | Single Page
Share: 

Filed under:ACR ConvergenceMeeting Reports Tagged with:ACR Convergence 2025DysautonomiaPOTS

Related Articles

    Under Pressure: Understanding Dysautonomia & POTS

    January 1, 2025

    Brit Adler, MD, provided a detailed analysis into the symptoms and management of patients with postural orthostatic tachycardia syndrome.

    Dr. Brit Adler Treks Across Glaciers & Forages for Mushrooms

    April 16, 2019

    In November 2017, Brit Adler, MD, an instructor in the Division of Rheumatology at Johns Hopkins University, Baltimore, was traveling across a glacier in the Cordillera Blanca mountain range in Peru. At nearly 15,000 feet high, the hikers in the caravan were secured to each other by ropes secured to harnesses. At that altitude, no…

    Experts Discuss 3 Frequently Overlooked Syndromes

    March 15, 2021

    ACR CONVERGENCE 2020—Myalgic encephalomyelitis/chronic fatigue syndrome, postural orthostatic tachycardia syndrome (POTS) and mast cell activation syndrome were the topics of the day in the ever-popular Curbside Consults session in November 2020. POTS An anxious woman with a chronic headache and constant myofascial pain in the neck and upper back, assorted gastrointestinal symptoms, chronic severe fatigue,…

    APS: What Rheumatologists Should Know about Hughes Syndrome

    February 17, 2016

    The problem that dogs the work of all of those treating patients with antiphospholipid syndrome (APS) is the apparent lack of knowledge of the syndrome, both by the general public, as well as by swaths of the medical fraternity. Perhaps it was ever thus—a syndrome less than 40 years old could be described as new,…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences